Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXX-401 in Healthy Adults
NCT05762276Phase 1Completed
- Sponsor
- Axxium Life Sciences
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Modified Peptides, Vaccines & Immunotherapeutics, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of VXX-401 in hypercholesterolemia (8 cohorts), sponsored by Axxium Life Sciences. Primary endpoints: Frequency of adverse events at 30 weeks, Immunogenicity at Week 30 and 1 more. Started Mar 2023; status: completed.
02
Drugs
VXX-401
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05762276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762276.